- Home
- GPRK vs TSHA Comparison
GPRK vs TSHA Comparison
Compare GPRK & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GPRK
- TSHA
- Stock Information
- Founded
- GPRK 2002
- TSHA 2019
- Country
- GPRK Colombia
- TSHA United States
- Employees
- GPRK N/A
- TSHA N/A
- Industry
- GPRK Oil & Gas Production
- TSHA Biotechnology: Pharmaceutical Preparations
- Sector
- GPRK Energy
- TSHA Health Care
- Exchange
- GPRK Nasdaq
- TSHA Nasdaq
- Market Cap
- GPRK 408.5M
- TSHA 403.7M
- IPO Year
- GPRK N/A
- TSHA 2020
- Fundamental
- Price
- GPRK $8.28
- TSHA $2.18
- Analyst Decision
- GPRK Strong Buy
- TSHA Strong Buy
- Analyst Count
- GPRK 2
- TSHA 8
- Target Price
- GPRK $12.50
- TSHA $6.63
- AVG Volume (30 Days)
- GPRK 302.7K
- TSHA 6.7M
- Earning Date
- GPRK 11-06-2024
- TSHA 11-13-2024
- Dividend Yield
- GPRK 7.05%
- TSHA N/A
- EPS Growth
- GPRK N/A
- TSHA N/A
- EPS
- GPRK 1.97
- TSHA N/A
- Revenue
- GPRK $716,838,000.00
- TSHA $9,915,000.00
- Revenue This Year
- GPRK N/A
- TSHA N/A
- Revenue Next Year
- GPRK $3.44
- TSHA N/A
- P/E Ratio
- GPRK $4.22
- TSHA N/A
- Revenue Growth
- GPRK N/A
- TSHA N/A
- 52 Week Low
- GPRK $7.24
- TSHA $1.19
- 52 Week High
- GPRK $11.25
- TSHA $4.32
- Technical
- Relative Strength Index (RSI)
- GPRK 51.57
- TSHA 56.47
- Support Level
- GPRK $7.96
- TSHA $1.96
- Resistance Level
- GPRK $8.86
- TSHA $2.34
- Average True Range (ATR)
- GPRK 0.32
- TSHA 0.26
- MACD
- GPRK 0.03
- TSHA 0.06
- Stochastic Oscillator
- GPRK 43.75
- TSHA 68.75
About GPRK Geopark Ltd
GeoPark Ltd is a Latin American oil and gas exploration and production company with assets in Colombia, Ecuador, Chile, Brazil and Argentina. The company generates revenue from the sale of crude oil, condensate and natural gas net of value-added tax and discounts related to the sale and overriding royalties due to the ex-owners of oil and gas properties where the royalty arrangements represent a retained working interest in the property.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.